Data from clinical trials of GM-CSF and G-CSF suggested an increase in collateral-dependent flow; however, the largest (n = 40 patient) study of patients with peripheral artery disease did not show a difference between the intervention and control groups. This evidence concerns the gene CSF2 and peripheral arterial disease.